David McDermott Hughes′ Response to Bram Büscher′s Review of Whiteness in Zimbabwe: Race, landscape, and the problem of belonging

by David McDermott Hughes
Published 2011-01-01

Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma

by Matthew Weinstock, David McDermott
Published 2015-12-01

219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients

by David McDermott, Michael Atkins, Ahmad Tarhini, Apoorva Ambavane, Agnes Benedict, Cho-Han Lee, Corey Ritchings, Brian Stwalley, Meredith Regan
Published 2020-11-01

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

by Tim Eisen, James Larkin, Christian Rothermundt, Brian Rini, David McDermott, Manuela Schmidinger, Viktor Gruenwald, Camillo Porta, Bernard Escudier, Stefanie Aeppli, Eric Innocents Eboulet, Stefanie Fischer, Jan Oldenburg, Aurelius Omlin, Cora Sternberg
Published 2020-11-01

347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

by Lucy Gilbert, Jameel Muzaffar, David McDermott, Vamsidhar Velcheti, Anna Spreafico, Valentina Boni, Christopher Hoimes, Ira Winer, Seth Rosen, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora Bruno, Elizabeth Dorn, Jessicca Rege
Published 2020-11-01

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

by Ann W. Silk, Ann W. Silk, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Brendan Curti, Janice M. Mehnert, Kim Margolin, David McDermott, Joseph Clark, Jenna Newman, Praveen K. Bommareddy, Praveen K. Bommareddy, Lisa Denzin, Lisa Denzin, Lisa Denzin, Saltanat Najmi, Saltanat Najmi, Azra Haider, Azra Haider, Weichung Shih, Michael P. Kane, Andrew Zloza, Andrew Zloza
Published 2020-01-01